CLD-601

CLD-601 is an investigational oncolytic virus and gene therapy being developed by Calidi Biotherapeutics for the treatment of undisclosed oncological indications. As part of Calidi's therapeutic pipeline, CLD-601 is designed to leverage the selective replication of oncolytic viruses within tumor cells to induce cell lysis and stimulate a systemic anti-tumor immune response. The therapy also incorporates gene therapy components to enhance its therapeutic efficacy, although the specific genetic payloads and molecular targets remain undisclosed by the developer. It represents a next-generation approach in Calidi's portfolio to address unmet needs in oncology through optimized viral delivery and potentiation.